Probiotics are live microorganisms that, when administered in adequate amounts, confer health benefits to the host. Their impact on drug bioavailability and efficacy, particularly in gastrointestinal disorders, has gained considerable interest. This paper explores how probiotics can modulate the pharmacokinetics and pharmacodynamics of various medications used in treating gastrointestinal conditions such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and peptic ulcers. Probiotics may influence drug absorption, metabolism, and excretion through mechanisms such as alteration of gut microbiota composition, enhancement of intestinal permeability, and modulation of drug-metabolizing enzymes.The review synthesizes findings from recent studies demonstrating that probiotics can enhance drug efficacy by improving gut health and reducing inflammation. For instance, certain probiotic strains have been shown to increase the bioavailability of drugs by optimizing intestinal flora and reducing gastrointestinal disturbances. Conversely, probiotics may also impact drug metabolism, potentially leading to altered drug levels and effects. The paper discusses both the positive and negative implications of probiotic-drug interactions and highlights the need for individualized therapeutic strategies. It also underscores the importance of clinical trials to establish clear guidelines for integrating probiotics into drug therapy regimens for gastrointestinal disorders. Overall, while probiotics hold promise for improving drug outcomes in gastrointestinal conditions, their effects on drug bioavailability and efficacy require further investigation to ensure safe and effective therapeutic use.